{"id":16637,"date":"2023-07-03T11:02:00","date_gmt":"2023-07-03T03:02:00","guid":{"rendered":"https:\/\/flcube.com\/?p=16637"},"modified":"2024-12-04T11:14:09","modified_gmt":"2024-12-04T03:14:09","slug":"beijing-sun-novo-and-zhejiang-anglikang-enter-licensing-agreement-for-hypertension-drug-candidate-nhkc-1","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=16637","title":{"rendered":"Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1"},"content":{"rendered":"\n

Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621<\/a>) has announced a significant licensing agreement with fellow Chinese firm Zhejiang Anglikang Pharmaceutical Co. Ltd (SHE: 002940<\/a>) concerning Sun-Novo’s drug candidate, NHKC-1. This development marks a collaborative effort between the two companies to co-develop a treatment for primary hypertension.<\/p>\n\n\n\n

NHKC-1: A Drug Candidate for Primary Hypertension<\/strong>
NHKC-1 is currently in development to treat primary hypertension and is the subject of a clinical study designed to assess its bioequivalence, efficacy, and safety. The partnership between Sun-Novo and Anglikang is valued at RMB 150 million (USD 20.7 million), which includes a research and development-linked milestone payment of RMB 75 million. This valuation is contingent upon the drug’s successful progression through development; if a similar product from another manufacturer achieves market approval before NHKC-1, the project value will be adjusted to RMB 100 million, with the milestone payment being adjusted accordingly.<\/p>\n\n\n\n

Post-Approval Plans and Roles<\/strong>
Following market approval, Zhejiang Anglikang Pharmaceutical is set to handle the manufacturing and marketing of NHKC-1, while Beijing Sun-Novo Pharmaceutical Research Co., Ltd will assume the role of Marketing Authorization Holder (MAH). This strategic division of responsibilities is aimed at leveraging the strengths of both companies to ensure the successful launch and distribution of NHKC-1 in the market.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1539,108,1262,1538,2604],"class_list":["post-16637","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-anglikang-pharmaceutical","tag-high-blood-pressure","tag-sha-688621","tag-she-002940","tag-sun-novo-pharmaceutical-research"],"yoast_head":"\nBeijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with fellow Chinese firm Zhejiang Anglikang Pharmaceutical Co. Ltd (SHE: 002940) concerning Sun-Novo's drug candidate, NHKC-1. This development marks a collaborative effort between the two companies to co-develop a treatment for primary hypertension.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=16637\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=16637\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-03T03:02:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-04T03:14:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16637#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16637\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1\",\"datePublished\":\"2023-07-03T03:02:00+00:00\",\"dateModified\":\"2024-12-04T03:14:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16637\"},\"wordCount\":221,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Anglikang Pharmaceutical\",\"High blood pressure\",\"SHA: 688621\",\"SHE: 002940\",\"Sun-Novo Pharmaceutical Research\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16637#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16637\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=16637\",\"name\":\"Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-03T03:02:00+00:00\",\"dateModified\":\"2024-12-04T03:14:09+00:00\",\"description\":\"Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with fellow Chinese firm Zhejiang Anglikang Pharmaceutical Co. Ltd (SHE: 002940) concerning Sun-Novo's drug candidate, NHKC-1. This development marks a collaborative effort between the two companies to co-develop a treatment for primary hypertension.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16637#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16637\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16637#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1 - Insight, China's Pharmaceutical Industry","description":"Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with fellow Chinese firm Zhejiang Anglikang Pharmaceutical Co. Ltd (SHE: 002940) concerning Sun-Novo's drug candidate, NHKC-1. This development marks a collaborative effort between the two companies to co-develop a treatment for primary hypertension.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=16637","og_locale":"en_US","og_type":"article","og_title":"Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=16637","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-03T03:02:00+00:00","article_modified_time":"2024-12-04T03:14:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=16637#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=16637"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1","datePublished":"2023-07-03T03:02:00+00:00","dateModified":"2024-12-04T03:14:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=16637"},"wordCount":221,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Anglikang Pharmaceutical","High blood pressure","SHA: 688621","SHE: 002940","Sun-Novo Pharmaceutical Research"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=16637#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=16637","url":"https:\/\/flcube.com\/?p=16637","name":"Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-03T03:02:00+00:00","dateModified":"2024-12-04T03:14:09+00:00","description":"Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with fellow Chinese firm Zhejiang Anglikang Pharmaceutical Co. Ltd (SHE: 002940) concerning Sun-Novo's drug candidate, NHKC-1. This development marks a collaborative effort between the two companies to co-develop a treatment for primary hypertension.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=16637#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=16637"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=16637#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16637"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16637\/revisions"}],"predecessor-version":[{"id":16640,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16637\/revisions\/16640"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}